Pharmaceutical giant Merck to manufacture flagship cancer drug Lynparza at new €1 billion Irish facility, dealing significant blow to UK's life sciences sector and raising fresh post-Brexit trade concerns.
Major pharmaceutical giants AstraZeneca, MSD (Merck), and Eli Lilly announce massive new investments in UK research and manufacturing, signalling a major vote of confidence in the British life sciences sector following the US election result.
Pharmaceutical giant AstraZeneca has paused plans for its new £500 million global headquarters in Cambridge, citing an 'unfavourable' UK economic climate and sending shockwaves through the business community.
Pharmaceutical giant AstraZeneca pauses its major £200m Cambridge research centre expansion, citing global strategic review and UK economic uncertainty in post-Brexit landscape.
A groundbreaking new hypertension drug, Baxdrostat, developed by AstraZeneca, has demonstrated remarkable success in clinical trials, potentially offering new hope for millions with treatment-resistant high blood pressure in the UK.
AstraZeneca's CEO highlights the critical role of the US market amid looming Trump tariffs, emphasising the need for stable trade policies to sustain pharmaceutical innovation.
Pharmaceutical giant AstraZeneca faces a sharp decline in share prices following an unfavourable US court ruling, sparking investor concerns.
Pharmaceutical giant AstraZeneca announces a bold $1.5bn US expansion despite looming tariff threats from the Trump administration, signalling confidence in transatlantic trade resilience.